Aberrant cell surface sialylation patterns have been shown to correlate with tumor progression and metastasis. However, the role of sialylation regulation of cancer multidrug resistance (MDR) remains poorly understood. This study investigated sialylation in modification on MDR in acute myeloid leukemia (AML). Using mass spectrometry (MS) analysis, the composition profiling of sialylated N-glycans differed in three pairs of AML cell lines. Real-time PCR showed the differential expressional profiles of 20 sialyltransferase (ST) genes in the both AML cell lines and bone marrow mononuclear cells (BMMCs) of AML patients. The expression levels of ST3GAL5 and ST8SIA4 were detected, which were overexpressed in HL60 and HL60/adriamycin-resistant (ADR) cells. The altered levels of ST3GAL5 and ST8SIA4 were found in close association with the MDR phenotype changing of HL60 and HL60/ADR cells both in vitro and in vivo. Further data demonstrated that manipulation of these two genes' expression modulated the activity of phosphoinositide-3 kinase (PI3K)/Akt signaling pathway and its downstream target thus regulated the proportionally mutative expression of P-glycoprotein (P-gp) and MDR-related protein 1 (MRP1), both of which are known to be involved in MDR. Blocking the PI3K/Akt pathway by its specific inhibitor LY294002 or by Akt small interfering RNA resulted in the reduced chemosensitivity of HL60/ADR cells. Therefore, this study indicated that sialylation involved in the development of MDR of AML cells probably through ST3GAL5 or ST8SIA4 regulating the activity of PI3K/Akt signaling and the expression of P-gp and MRP1.
INTRODUCTION
Acute myeloid leukemia (AML), the most common type of leukemia in adults, has the lowest survival rate among all leukemias. 1 It is a clonal malignancy of the hematopoietic system characterized by accumulation of immature cell populations in the bone marrow or peripheral blood. 2 Multidrug resistance (MDR) is a major challenge to the successful treatment of AML. Classic MDR is the consequence of overexpression of transporter proteins, for example, P-glycoprotein (P-gp) and MDRrelated protein 1 (MRP1), belonging to the ATP-binding cassette family, which lead to lower intracellular drug accumulation and thus reduce cellular toxicity of chemotherapeutic agents. 3 Nowadays, many researchers are struggling to adequately evaluate the relationship between glycan alterations and resistance to chemotherapy of cancer cells. However, there is still little information about the role of glycosyltransferases in the development of leukemia MDR in spite of the modification of glycan structures have been observed in drug-resistant leukemia cells. 4, 5 Cell surface glycoproteins commonly contain sialic acid (SA) as a monosaccharide located on the nonreducing terminus of glycans. Evidence from both patient histochemical analysis and experimental tumor models demonstrates that altered sialylation involves in a variety of biological processes, including cell-cell communication, cell-matrix interaction, adhesion and protein targeting. 6, 7 Sialyltransferases (STs) are a family of anabolic enzymes, consisting of 20 members that are subjected into three subfamilies. These glycosyltransferases convert SA from cystidine-5-monophospho-N-acetylneuraminic acid to glycoproteins or glycolipids. 8 Alpha-2, 3-sialyltransferases mediate the transfer of SA with an alpha 2, 3-linkage to it with terminal Gal residues (ST3Gal I-VI). Alpha-2, 6-sialyltransferases mediate the transfer of SA with an alpha 2, 6-linkage to it with terminal Gal (ST6Gal I-II) or GalNAc residues (ST6GalNAc I-VI). Alpha-2, 8-sialyltransferases mediate the transfer of SA with an alpha 2, 8-linkage (ST8Sia I-VI) to it with other SA residues. 9 Although the modification of sialylation in solid tumors has been documented in details, 10, 11 there are not many reports in case of blood cancer. ST3Gal V was found predominantly expressed in childhood acute lymphoblastic leukemia. 12 High level of ST3Gal III, an enzyme catalyzing sialyl-Lewis X synthesis, produced cellular resistance to Taxol and thus reduced the efficacy of Taxol therapy. 13 Elevated mRNA levels of ST6Gal I and ST3Gal V positively correlated with the high risk of pediatric acute leukemia. 12 Endogenous expression of ST6GalNAc I in chronic myeloid leukemia cell line K562 was associated with the expression of the STn O-glycan related to a lack of response to chemotherapy. 14 Yamada et al. 15 confirmed ST6GalNAc IV as the major enzyme controlling the expression of sialyl-T antigen in leukemia cell lines. ST8Sia I (GD3 synthase) was downregulated in childhood acute lymphoblastic leukemia, while it was upregulated in adult T-cell leukemia cell lines. 12 Polysialic acid formed by ST8Sia II and ST8Sia IV has been found on the unidentified proteins in basophilic leukemia cell lines. 16 In order to inhibit MDR of AML, targeting of ST genes could be applied to cancer therapy.
Phosphoinositide-3 kinase (PI3K)/Akt signaling activation is implicated involving in the progression of a wide variety of neoplasias. 17 Recent studies illustrate that aberrant activation of PI3K/Akt pathway leads to the short-term survival and drug resistance of different types of human neoplasm cells. 18, 19 Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. 20 However, little is known regarding the PI3K/Akt signaling pathways on ST-mediated leukemia MDR.
In order to understand the role of ST gene family in regulation of MDR in AML, this study aimed to investigate the sialylated oligosaccharide alterations and mRNA expression levels of ST genes in three pairs of AML cell lines and in bone marrow mononuclear cell (BMMC) isolated from the diagnostic AML patients, as well as the possible mechanisms via PI3K/Akt pathway.
RESULTS

MALDI-MS analysis of N-glycan composition profiling from AML cell lines
Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (MS) analysis was utilized to evaluate the N-glycan composition profiling of HL60 and HL60/ADR cell lines. Figure 1 showed the MS spectra of N-glycans released from cell membranes and the observed MS signals of the N-glycans (peaks 1-35 in Figure 1a ) and the assigned N-glycan signals were summarized in Table 1 . The observed signal intensities in the mass spectra were presented as a histogram (Figure 1b) , with the estimated monosaccharide composition. High-mannose glycans (peaks 4, 6, 9, 13 and 16) were observed in both cell lines ( Table 1 ). The N-glycans detected in HL60/ADR cells showed remarkably different profiles vs those of HL60 cells. The peaks at 5 and 30 were exclusively detected only in the HL60/ADR cell line.
HL60/ADR cells also showed higher incidence of additional significant peaks at 1, 2, 7, 10, 11, 17, 21, 23, 31 and 34 (X2-fold). Peaks 14, 15, 25 and 28 (X2-fold) clearly showed a significant increase in HL60 cell line. Surprisingly, the most significant increase peaks corresponding to sialylated oligosaccharides were observed at peaks 17, 21, 23, 31 and 34 in HL60/ADR cells. The sialylated oligosaccharides observed at peaks 15, 25 and 28 also showed significant increase in HL60 sample.
Differential expression of ST family in three pairs of AML cell lines Real-time PCR analysis showed that the expression of ST gene family was differed between the three pairs of AML cell lines. A common feature was that the expression levels of ST8SIA4 (5.81-folds), ST6GAL1 (4.56-folds), ST3GAL4 (3.18-folds) and ST6GALNAC4 (3.01-folds) were remarkably high in three MDR cells. In addition, drug-sensitive cells showed higher expressional levels of ST3GAL5 (5.19-folds), ST8SIA6 (4.17-folds) and ST3GAL1 (2.72-folds). No statistically significant differences were found in the expression levels of ST3GAL2, ST3GAL3, ST6GAL2, ST6GAL-NAC1, ST6GALNAC2, ST6GALNAC6, ST8SIA1 and ST8SIA5 mRNA, whereas ST3GAL6, ST6GALNAC3, ST6GALNAC5, ST8SIA2 and ST8SIA3 were undetectable in both drug-sensitive cells and MDR cells (Figures 2a-e).
Altered expression of ST8SIA4 modulates chemosensitivity of AML cells in vitro and in vivo
Owing to the significant increase of ST8SIA4 mRNA expression in HL60/ADR cells, ST8SIA4 was silenced, by short hairpin RNA (shRNA), so as to elucidate its direct effect on the chemosensitivity of HL60/ADR cells. As shown in Figures 3a and b, the expression level of ST8SIA4 was significantly reduced in HL60/ADR-shRNA transfectants compared with those in the controls both at transcription and protein level. Furthermore, a-2, 8 sialylation level detected by fluorescein isothiocyanate-conjugated Siglec7 Figure 1 . Differential N-glycan composition of HL60 and HL60/ADR cell lines. (a) MALDI-TOF MS spectra of permethylated N-glycans released from HL60 and HL60/ADR cells, respectively. (b) Histograms of relative intensities of the differential glycan signals were observed. The signals indicated with Arabic numerals are summarized in Table 2 . on the cell surface was also found reduced in HL60/ADR-ST8SIA4 shRNA1 cells ( Figure 3c ).
As depicted in Figure 3d , in addition to adriamycin, HL60/ADR cells were also resistant to other chemotherapeutic drugs including paclitaxel and vincristine. The IC 50 values for the drugs were greater in the HL60/ADR group than those in the HL60 group (Figure 3d ), which indicated that HL60/ADR cells awarded MDR characteristics. The IC 50 values for the drugs were significantly less in the HL60/ADR-ST8SIA4 shRNA1 groups than those in the HL60/ADR-control shRNA groups, suggesting that cell proliferation was inhibited and chemosensitivity was remarkably restored (Figure 3d ).
Nude mice bearing HL60, HL60/ADR, HL60-control shRNA and HL60/ADR-ST8SIA4 shRNA1 xenografts were used to determine the treatment efficacy of adriamycin by measuring tumor volumes. Figure 3e showed that a significant reduction of mean tumor volume of HL60 tumors was observed, as compared with HL60/ADR groups. The mean tumor volume was significantly less in the HL60/ADR-ST8SIA4 shRNA1 groups than those in the HL60/ADR-control shRNA groups, and the effect of concomitant application of adriamycin. Immunohistochemical (IHC) staining analysis of the tumor sections revealed that the expression of ST8sia IV was decreased in the mouse group treated with ST8SIA4 shRNA1 compared with that in untreated group (Figure 3f ).
To further investigate the effect of ST8SIA4 on chemoresistance, ST8SIA4 expression vector was transfected in HL60 cells and higher expression levels of ST8SIA4 were detected in HL60/ ST8SIA4 cells (Figures 4a-c and f). The chemoresistance of HL60 cells was increased after the transfection of the ST8SIA4 expression vector in vitro and in vivo (Figures 4d and e ).
We evaluated the expression of relevant substrate in the aberrantly expressed ST8SIA4 cell lines. CD147 is N-glycoprotein, which was analyzed by way of immunoprecipitation. A remarkable change of CD147 expression was observed in HL60/ADR-ST8SIA4 shRNA1 and HL60/ST8SIA4 cells compared with those in the control cells. Siglec7 lectin blotting also showed the same tendency, suggesting that CD147 was a specific substrate of ST8SIA4 ST ( Supplementary Figures S1a and b ).
Altered expression of ST3GAL5 regulates chemosensitivity of AML cells in vitro and in vivo
As it was found that the mRNA and protein levels of ST3GAL5 were decreased notably in HL60-ST3GAL5 shRNA transfectants (Figures 5a and b ), we targeted ST3GAL5 to determine whether changed expression of ST3GAL5 could influence chemosensitivity of HL60 and HL60/ADR cells. Fluorescence intensity on MAL revealed less a-2, 3 sialylation in HL60-ST3GAL5 shRNA1 cells than Figure 5c ). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay results showed that the IC 50 values for the drugs were greater in the HL60/ADR group than those in the HL60 group ( Figure 5d ). The IC 50 values for the drugs were significantly increased in HL60-ST3GAL5 shRNA1 cells groups compared with those in the HL60-control shRNA groups (Figure 5d ).
Tumor volumes were measured and compared between the groups with or without adriamycin treatment. Figure 5e displayed that a significant reduction of mean tumor volume of HL60 tumors was observed, as compared with HL60/ADR groups. In the group of mice bearing HL60 tumors, tumor volumes with adriamycin treatment were lower than those without. But in the group of mice bearing HL60-ST3GAL5 shRNA tumors, tumor volumes increased significantly even after adriamycin treatment. Reduced expression level of ST3Gal V in tumor cells of HL60-ST3GAL5 shRNA1 was also validated by IHC staining (Figure 5f ).
In order to determine whether overexpression of ST3GAL5 could enhance chemosensitivity of HL60/ADR cells, HL60/ADR cells were then transfected with ST3GAL5 expression vector and higher levels of ST3GAL5 were detected in HL60/ADR/ST3GAL5 cells (Figures 6a and b ). The chemosensitivity of HL60/ADR cells was increased with the ST3GAL5 expression vector transfection in vitro and in vivo (Figures 6d and e ). IHC staining and flow cytometry analysis revealed elevated expression of ST3Gal V in HL60/ADR/ST3GAL5 cells (Figures 6c and f) .
Further on, we investigated the expression of relevant substrate in the aberrantly expressed ST3GAL5 cell lines. CD147 and MAL lectin showed no difference in expression among the six groups, suggesting that CD147 was not a relevant substrate of ST3GAL5 ST ( Supplementary Figures S1c and d ).
Effect of ST3GAL5 or ST8SIA4-activated PI3K/Akt signaling pathway on the expression of P-gp and MRP1 Here, we investigated whether ST3GAL5 or ST8SIA4 activated the PI3K/Akt pathway and whether this pathway was involved in ST3GAL5 or ST8SIA4-mediated cell MDR. Western blotting (Figures 7b and c) showed that the levels of the main molecules of PI3K/Akt signaling pathway, P110a (the catalytic subunit of PI3K), phosphorylation Akt at Ser473 and Thr308, and its downstream effector nuclear factor-kB (NF-kB) were significantly increased in HL60/ST8SIA4 cells and HL60-ST3GAL5 shRNA1 cells, whereas it decreased in HL60/ADR/ST3GAL5 cells and HL60/ADR-ST8SIA4 shRNA1 cells (Figures 7a and d ). However, there was no change in the total amount of Akt protein. Interestingly, we also revealed the same tendency of PI3K/Akt/mammalian target of rapamycin (mTOR) pathway on stimulation with ST3GAL5 or ST8SIA4 (Supplementary Figure S2) .
Moreover, we investigated whether ST3GAL5 or ST8SIA4 could influence the expression of P-gp and MRP1. Interestingly, flow cytometric analysis (Figures 7f and g) illustrated that elevated expression levels of P-gp and MRP1 were detected in HL60/ST8SIA4 cells and HL60-ST3GAL5 shRNA1 cells compared with those in the control groups. In addition, HL60/ADR cells expressed lower levels of P-gp and MRP1 with ST8SIA4 suppression and ST3GAL5 overexpression (Figures 7e and h) .
PI3K/Akt inhibition modulates the chemoresistance of HL60/ADR cells both in vitro and in vivo
The effect of PI3K/Akt signaling activity on chemoresistance of HL60/ADR cells was explored by pharmacologic inhibition of the PI3K/Akt pathway. By western blotting, HL60/ADR cells treated with LY294002 or Akt small interfering RNA (siRNA) exhibited apparently decreased expression levels of the main signal molecules of PI3K/Akt pathway (Figure 8a ). As seen in Figure 8b , the inhibition of PI3K/Akt pathway resulted in the HL60/ADR cells susceptible to chemotherapy. The similar results were also obtained in in vivo chemosensitivity analysis that reduced tumor volumes were detected in mouse group bearing HL60/ADR tumors with impaired PI3K/Akt signaling (Figure 8c ). Altered expression levels of the main signal molecules of PI3K/Akt pathway in mouse group bearing HL60/ADR tumors with LY294002 or Akt siRNA treatment were also validated by IHC staining, as shown in Figure 8d . Moreover, the inhibitor of PI3K/Akt or silencing Akt reduced the expression of P-gp and MRP1 (Figure 8e ).
Differential expression of ST gene family in AML patients
Expression of MDR-related marker, ST gene family presenting in BMMC of AML patients is summarized in Table 2 . The frequency of P-gp positivity was 90.8% (69 of 76) in the AML patients. The BMMC were first divided into six groups, M2, M2/MDR, M3, M3/MDR, M5 and M5/MDR, and evaluated the mRNA expression level of ST gene family. The groups of M2/MDR, M3/MDR and M5/MDR showed significantly high ST3GAL4 (P ¼ 0.002; P ¼ 0.006; P ¼ 0.009), ST6GAL1 (P ¼ 0.004; P ¼ 0.002; P ¼ 0.004), ST6GALNAC4 (P ¼ 0.003; P ¼ 0.001; P ¼ 0.003) and ST8SIA4 (P ¼ 0.001; P ¼ 0.004; P ¼ 0.008) mRNA expression compared with those of the chemosensitive group. In contrast, group of M2, M3, M5 without MDR showed significantly upregulated ST3GAL1 (P ¼ 0.032; P ¼ 0.002; P ¼ 0.025), ST3GAL5 (P ¼ 0.001; P ¼ 0.001; P ¼ 0.003) and ST8SIA6 (P ¼ 0.002; P ¼ 0.001; P ¼ 0.002) expression compared with AML/ADR group. Expression of the other members of ST family showed no difference between the two groups, while ST3GAL6, ST6GALNAC3, ST6GALNAC5, ST8SIA2 and ST8SIA3 were detected slightly.
DISCUSSION
MDR is the major obstacle to the efficiency of chemotherapy in the treatment of leukemia. 21 In this study, we explored the possible mechanism of sialylation modification on MDR in human AML cell lines. We also investigated the differential expression of ST family, which was reported to be correlated with clinicopathological characteristics in AML patients.
Recent development in MS technology has fueled highthroughput analyses of glycoproteins. 22, 23 MS technology as a novel methodology provides high sensitivity and more rapid glycan analysis. 24 Zhang et al. 5 have investigated novel N-glycan changes involved in MDR between leukemia cell line K562 and adriamycin-resistant K562/ADR by MALDI-TOF MS. To identify sialylated N-glycan associated with MDR of human AML, we used MS method to analyze the composition profiling of N-glycans. We compared the total N-glycans from HL60 and HL60/ADR cell lines, and found marked differences in N-glycan profiles between these two groups (Figure 1 , Table 1 ). A major population of N-glycans detected in HL60 and HL60/ADR cells was corresponded to highmannose structures (peaks 4, 6, 9, 13 and 16). The peaks at 5 and 30 were exclusively detected only in the HL60/ADR cell line. Major peaks (peaks 1, 2, 7, 10, 11, 17, 21, 23, 31 and 34) corresponded to sialylated oligosaccharides originating from HL60/ADR cells showed a significant increase (X2-fold). Moreover, peaks 14, 15, 25 and 28 corresponded to sialylated oligosaccharides originating from HL60 cells also showed a significant increase (X2-fold). Therefore, monitoring of the sialylated N-glycan profile would be an important step in the prevention of tumor MDR and would increase our understanding of MDR mechanisms.
Aberrant expression of sialylated glycans in various cancers is recognized as prognostic factors and potential targets for therapeutic approaches. 25 Malignant cell surface properties are generally changed, which mainly due to altered sialoglycoconjugates expressed on the plasma membrane. 26 The biosynthetic pathway of sialylated glycans in leukemia pathogenesis highlighted the importance of ST in AML. In this study, we revealed the differential expression of ST genes in three pairs of AML cell lines. All MDR cells were characterized by higher levels of ST8SIA4 (5.81-fold, Figure 2 ) whereas parental cells expressed more ST3GAL5 (5.19-fold), suggesting that the AML cell lines displayed altered a2, 3-and a2, 8-linked sialylation.
ST3GAL5 encodes lactosylceramide a-2, 3-sialyltransferase that catalyzes the formation of ganglioside GM3. GM3 is a sialylated trisaccharide antigen richly expressed by a number of tumors and thus becomes an important molecular target in the development of novel diagnostic and therapeutic strategies for cancers. 27 ST8SIA4 encodes N-acetylgalactosaminide a-2, 8-sialyltransferase IV (ST8Sia IV) that catalyzes the polycondensation of a-2, 8-linked SA required for the synthesis of polysialic acid, a modulator of the adhesive properties of neural cell adhesion molecule, which is 28 It is of interest to know whether the change of ST3GAL5 or ST8SIA4 confers the alteration of MDR is in leukemia cells. Our former work demonstrated that the expression of ST3GAL5 or ST8SIA4 involved in drug resistance development in chronic myeloid leukemia cell lines K562 and K562/ADR. 5 The present investigation illustrated that the altered level of ST3GAL5 or ST8SIA4 led to drug-resistant phenotype changes of HL60 and HL60/ADR cells both in vitro and in vivo (Figures 3-6 ). On the basis of these results, we hypothesized that ST3GAL5 or ST8SIA4 may function as a pivotal modulator to MDR in AML. N-glycans bind proteins, and the combinations of glycan and protein may be important for their function. 29, 30 In this study, we analyzed the expressions of CD147 in AML cell lines to identify specific, relevant substrates of the aberrantly expressed STs. CD147 is a highly N-glycosylated immunoglobulin superfamily transmembrane protein that is composed of two extracellular immunoglobulin domains, which contribute to a highly N-glycosylated HG-CD147 (B40-60 kDa) and a low glycosylated form, LG-CD147 (B33 kDa). 31 Our previous results showed that altered N-glycosylation of CD147 was found in K562/ADR cells, and further suggested a link between defective N-glycosylation of K562/ADR cells and drug resistance. 5 In this study, the results confirmed that CD147 was a specific substrate of ST8SIA4 ST, rather than a relevant substrate of ST3GAL5 ST (Supplementary Figure S1 ). PI3K/Akt signaling pathway is reported to be over-activated in AML cells and has an essential role in proliferation, drug resistance, motility, invasion and inhibition of apoptosis in cancer cells. [32] [33] [34] [35] PI3K/Akt inhibition modulates MDR and activates NF-kB in murine lymphoma cell lines. 36 Inhibition of the PI3K/mTOR pathway is a promising therapeutic approach in patients with acute lymphoblastic leukemia. 37 A number of studies also have demonstrated that GM3 gangliosides inhibit phosphorylation of the epidermal growth factor receptor that results in inhibition of PI3K/Akt signaling in varied cell types. 38, 39 Neural cell adhesion molecule-mediated adhesion leads to activation of various intracellular signal transduction pathways, including the Rasmitogen-activated protein kinase and the PI3K/Akt pathways. 40 In this study, we found that a novel mechanism by which MDR of AML cells can be developed and changed, that is, MDR is induced through activation of the PI3K/Akt pathway by sialylation modification. The resistant cell line HL60/ADR exhibited higher PI3K/Akt activity than the sensitive one, which was in accordance with the MDR phenotype. Suppression of ST3GAL5 or ST8SIA4 markedly modulated the activity of PI3K/Akt pathway and its downstream target NF-kB and mTOR in AML cell lines (Figures 7a-d and Supplementary Figure S2 ). In addition, inhibition of the PI3K/Akt pathway with LY294002 or Akt gene silencing by siRNA pre-treatment reversed chemoresistance of HL60/ADR cells (Figures 8b and c) . These results indicated that ST3GAL5 or ST8SIA4-modulated MDR in AML cell lines is, at least in part, PI3K/Akt dependent.
To date, tremendous evidence indicates that tumor cells maintain the MDR through the PI3K/Akt pathway enhancing drug efflux by ATP-binding cassette transporters. 41 As two main members of ATP-binding cassette transporters, P-gp and MRP1, are frequently used as markers to screen MDR patients clinically. PI3K inhibitor, LY294002, therefore has therapeutic potential in the treatment of MRP1-mediated drug resistance when combined with doxorubicin, 42 as it is able to block P-gp expression in mouse leukemic cell lines. 43 A recent report in acute myelogenous leukemia has demonstrated that MRP-1 but not P-gp efflux was inhibited by the PI3K inhibitor wortmannin. 41 Moreover, constitutive activation of PI3K/Akt is associated with the expression of ST3GAL5 and ST8SIA4. [38] [39] [40] Therefore, a close association is found between the levels of ST3GAL5 and ST8SIA4 and the levels of phosphorylated Akt, as well as P-gp, MRP1 expression in leukemic cells. In this study, we showed that, the levels of P-gp and MRP1 had a proportional relationship with the expression of ST3GAL5 or ST8SIA4 and the activity of PI3K/Akt signaling in HL60 or HL60/ADR cell lines. As ST3GAL5 or ST8SIA4 was observed as regulatory gene for the activity of PI3K/Akt signaling, we assume that ST3GAL5 or ST8SIA4 may regulate the expression of P-gp and MRP1 through PI3K/Akt pathway, thereby promoting MDR of leukemia cells.
Although the clinical outcome of AML has been improved with advancements in chemotherapy, MDR remains a critical challenge for successful treatment. A great number of AML (including M2, M3 and M5) patients were examined and analyzed in this study, whereas 490% of the AML patients were found resistant to the anticancer drugs. ST3GAL4, ST6GAL1, ST6GALNAC4 and ST8SIA4 were expressed at a high level in BMMC of a significant proportion of M2/MDR, M3/MDR and M5/MDR patients, whereas expression of ST3GAL1, ST3GAL5 and ST8SIA6 were at a high level in BMMC of a number of cases M2, M3 and M5 without MDR. Once again the findings from the clinical samples confirm that altered levels of these genes were probably associated with MDR phenotype in AML. On the basis of the above results, it may be possible to utilize differential expressional ST genes as useful leukemia biomarkers for clinical diagnosis of drug-resistant leukemia and as potential targets for therapeutic approaches in the future.
In summary, our work reveals differential expression patterns of ST genes in three pairs of AML cell lines and in BMMC of the AML patients. Altered ST3GAL5 and ST8SIA4 presented the unusual property of association with MDR of AML cells via regulating the PI3K/Akt signaling pathway and the expression of P-gp and MRP1. MDR in AML is a multifactorial phenomenon and targeting these molecules seems to be a feasible approach to clinical diagnosis and treatment of MDR AML.
MATERIALS AND METHODS
Parental AML cell culture Three AML cell lines, including an acute myelogenous leukemia (M2) cell line HL60, an acute promyelocytic leukemia (M3) cell line NB4 and a leukemic monocytic lymphoma (M5) cell line U937 were obtained from the KeyGEN Company (Nanjing, China). All cell lines were cultured as previously described. 44 Adriamycin (Sigma, St Louis, MO, USA) was added to parental cell cultures in stepwise increasing concentrations from 0.1 to 5 mg/ml for 2 months to develop an ADR subline, namely HL60/ ADR, NB4/ADR and U937/ADR, correspondingly. To maintain the MDR phenotype, the complete medium of the resistant cell clones were supplemented with 1.0 mg/l adriamycin. ADR cells were maintained in 
Samples from leukemia patients
A total of 76 previously untreated AML patients comprising 53 men and 23 women, with age ranging from 12 to 79 years (median age of 42 years), and 7 healthy donors were included in this study. The diagnosis of AML was based on cytomorphology, cytochemistry, multiparameter flow cytometry, immunology, molecular genetics and cytogenetics, and the leukemic subtypes of AML were determined according to the French-American-British classification as follows: 35, 27 and 14 cases of M2, M3 and M5, respectively. All AML patients who were obtained from June 2010 to May 2012 at the First Affiliated Hospital of Dalian Medical University (Dalian, China) provided written informed consent, and the institutional ethics committees approved the study as well as contents of the written consent. Bone marrow samples were collected at diagnosis and before treatment. BMMC were isolated by Ficoll-Hypaque density gradient centrifugation and were cultured in plastic dishes to remove adherent cells at 37 1C for 24 h. Freshly separated non-adherent cells were maintained in modified Dulbecco's medium containing 10% fetal bovine serum, 10 mM b-mercaptoethanol, 2 mM L-glutamine, 50 ng/ml human stem cell factor, 10 ng/ml human interleukin-3 and 10 ng/ml human interleukin-6. Patients' clinical characteristics were given in Table 3 .
Membrane protein extract and release of N-glycans from cell membrane proteins
Membrane protein extract has been described previously. 8 For releasing of N-glycans, three 100 mg aliquots of lyophilized cell membrane proteins were first digested with trypsin (10 mg) and chymotrypsin (10 mg) dissolved in 25 mM ammonium bicarbonate (25 ml) at 37 1C for 18 h. The digest was left in a water bath (85 1C, 5 min) and after cooling N-linked oligosaccharides were released from peptides by treatment with PNGaseF enzyme (2 ml; 6 U) at 37 1C (18 h) followed by Pronase digestion (10 mg) at 37 1C (8 h). During the incubation time, the reaction sample was mixed occasionally. The released N-glycans were purified using an Oasis HLB cartridge (60 mg/3 ml; Waters, Milford, MA, USA) and then were lyophilized.
MS analysis
The mass spectra were carried out in reflectron-positive ion mode with MALDI-TOF MS ((Bruker Corp., Billerica, MA, USA). To increase sensitivity and provide more informative fragmentation, the released glycans were permethylated and further characterized by MALDI-TOF MS. For the type of MALDI analysis of the permethylated glycans, 2,5-Dihydroxybenzoic acid (2,5-DHB) was used as the matrix. All MS spectra were obtained from Na þ adductions.
Real-time PCR analysis
Total RNA was isolated with Trizol reagents (Gibco BRL, Rockville, MD, USA), treated by QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA) and QuantiTect SYBR Green PCR Kit (Qiagen). The primer pairs for PCR are listed in Table 4 . Level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was measured for standardization and calculated as 2 À (Ct Target gene À Ct GAPDH ) .
Western blot analysis
Western blot analysis was carried out as described previously. 44 Briefly, samples (20 mg protein) were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis. After transfer of proteins onto the polyvinylidene difluoride membrane, the blots were probed with the following antibodies: rabbit anti-human ST8Sia IV, ST3Gal V, PI3K p110a, p-Akt 308, p-Akt 473, Akt, NF-kB antibodies (Abgent, Cambridge, UK, 1:1000 dilution), and then incubated with secondary antibody anti-rabbithorseradish peroxidase (1:2000 diluted, Santa Cruz Biotech, Santa Cruz, CA, USA). CD147, mTOR, p-mTOR ser2448 , p-p70S6K Thr389 and GAPDH antibody (1:200 diluted, Santa Cruz Biotech) was used as a control.
Deregulation of ST3GAL5 or ST8SIA4 by RNA interference RNA interference was performed as previously described. 44 The cell cultures were transfected with ST3GAL5 or ST8SIA4-specific shRNA, and scrambled shRNA used as the negative control. ST3GAL5 shRNA or ST8SIA4 shRNA was mixed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Transfer cells were cultured and incubated at 37 1C for 6 h, followed by incubation with complete medium for additional 24 h. The cell transfection efficiency was 85% by fluorescent microscope and the cell viability was 90% by Trypan blue dye exclusion assay.
Overexpression of ST3GAL5 or ST8SIA4
The human ST3GAL5 and ST8SIA4 coding sequences were obtained from TaKaRa Company (Dalian, China) and were inserted into the pEGFP-N2 vector (Invitrogen), respectively, using EcoRI, XhoI sites. Cells were transfected with 5 mg of target gene expression vector or empty vector in 100-mm dishes using PolyFect Transfection Reagent (Qiagen) according to the manufacturer's instruction. After 4 weeks of screening, the cell lines stably expressing ST3GAL5 (HL60/ADR/ST3GAL5) and ST8SIA4 (HL60/ Modification of sialylation in human AML MDR H Ma et al ST8SIA4), empty vector (HL60/ADR/mock, HL60/mock) were established. The cell transfection efficiency was 79% and the survival rate was 90%.
In vitro drug cytotoxic assay Drug resistance was evaluated by MTT assay as previously described. 44 Briefly, cells (1 Â 10 4 ) were plated in 96-well plate and allowed to grow for 48 h before the addition of MTT. The spectrometric absorbance was measured at 490 nm by microplate reader (Model 680; Bio-Rad, Hercules, CA, USA).
In vivo chemosensitivity assay
Animal studies were performed as previously described. 44 Briefly, when mice bearing palpable tumors, HL60, HL60/mock, HL60/ST8SIA4, HL60-control shRNA, HL60-ST3GAL5 shRNA-1, HL60/ADR, HL60/ADR/ ST3GAL5, HL60/ADR-control shRNA and HL60/ADR-ST8SIA4 shRNA-1 tumor-bearing mice were randomly divided into control and treatment groups (n ¼ 6 animals per group). The treatment groups received 7 mg/kg adriamycin intraperitoneally three times a week for 3 weeks, and the control groups received physiological saline alone. The tumor volume was calculated by the following formula: tumor volume ¼ 1/2(length Â width 2 ).
IHC staining analysis
Visible tumors were removed from the mice and IHC was performed on paraffin-embedded sections. The slides were dried, deparaffinized and rehydrated. After deparaffinization and blocking of endogenous peroxidase, the slides were labeled overnight at 4 1C with antibodies (Abcam, Cambridge, UK) at a dilution of 1:200. The following staining was performed at 37 1C for 60 min with secondary streptavidin-horseradish peroxidase-conjugated antibody (Santa Cruz Biotech). Finally, the sections were counterstained with hematoxylin and cover slipped.
Inhibition of the PI3K/Akt signaling LY294002 (Sigma) or Akt siRNA was used to suppress the activity of the PI3K/Akt signaling in HL60/ADR cells. Briefly, cells (1 Â 10 4 cells per well) were incubated with dimethylsulphoxide, the PI3K inhibitor LY294002 (10 mM) dissolved in dimethylsulphoxide, Akt control siRNA and Akt siRNA, and collected after 24 h.
Flow cytometry analysis
Flow cytometry analysis has been described previously. 44 For surface staining of P-gp and MRP1, aliquots of cells were incubated with fluorescein isothiocyanate-anti-human P-gp, MRP1 (Abcam) or an isotype control antibody (Santa Cruz Biotech). For detection of a-2, 3 and a-2, 8 sialylation, cell lysates were incubated with fluorescein isothiocyanate-MAL or Sig 7 lectin (Sigma). After repeated centrifugation at 1000 r.p.m., labeled cells were resuspended in 0.2 ml phosphate-buffered saline and were analyzed with FACSCalibur (BD Biosciences, San Jose, CA, USA).
Statistical analysis
Data were expressed as mean ± s.d. and Student's t-test was carried out. Po0.05 was considered statistically significant.
